Orkambi Efficacy Sways FDA Panel Despite Uncertainty Over Lumacaftor’s Role
This article was originally published in The Pink Sheet Daily
Executive Summary
Pulmonary-allergy drugs panel endorses approval of Vertex’s lumacaftor/ivacaftor fixed-dose combination for cystic fibrosis and suggests the question of whether the combination would be more or less effective than ivacaftor monotherapy is not relevant.
You may also be interested in...
Celtaxsys To Hash Out Phase III Cystic Fibrosis Endpoints With US FDA
Private start-up's acebilustat failed to improve lung function in Phase II, but the anti-inflammatory showed large numerical reductions in pulmonary exacerbations, which can be fatal.
Electronic Records: US FDA Updates Guidelines On Use In Clinical Investigations
Revised draft guidance includes recommendations on preparing for FDA inspections, considerations for real-world data and digital health technologies, and the need for service level agreements between sponsors and IT providers.
Biogen/Ionis’ Tofersen: US FDA Considering Both Accelerated And Regular Approval In ALS
FDA seeks advisory committee input on whether there is ‘convincing evidence’ to support regular approval for treatment of SOD1-ALS patients even though lone Phase III trial failed its primary endpoint; companies filed for accelerated approval on the basis that a reduction in plasma neurofilament light chain is reasonably likely to predict clinical benefit.